Patrick J. Haley Sells 1,000 Shares of Exelixis, Inc. (NASDAQ:EXEL) Stock

Exelixis, Inc. (NASDAQ:EXEL) insider Patrick J. Haley sold 1,000 shares of the company’s stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $20.96, for a total transaction of $20,960.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Patrick J. Haley also recently made the following trade(s):

  • On Monday, June 10th, Patrick J. Haley sold 1,000 shares of Exelixis stock. The shares were sold at an average price of $20.23, for a total transaction of $20,230.00.
  • On Friday, May 10th, Patrick J. Haley sold 1,000 shares of Exelixis stock. The shares were sold at an average price of $19.58, for a total transaction of $19,580.00.

NASDAQ:EXEL traded up $0.07 during midday trading on Friday, hitting $20.98. The company’s stock had a trading volume of 1,548,914 shares, compared to its average volume of 3,352,340. Exelixis, Inc. has a fifty-two week low of $13.42 and a fifty-two week high of $25.31. The company’s 50 day simple moving average is $20.56. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.48 and a current ratio of 7.56. The company has a market capitalization of $6.30 billion, a price-to-earnings ratio of 14.67, a P/E/G ratio of 0.49 and a beta of 1.93.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.24 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.24. Exelixis had a net margin of 75.97% and a return on equity of 37.21%. The company had revenue of $215.49 million for the quarter, compared to the consensus estimate of $206.06 million. During the same quarter in the prior year, the company earned $0.40 EPS. Exelixis’s quarterly revenue was up .8% on a year-over-year basis. On average, sell-side analysts anticipate that Exelixis, Inc. will post 0.92 earnings per share for the current fiscal year.

A number of large investors have recently modified their holdings of the stock. Oakbrook Investments LLC boosted its position in Exelixis by 1.4% in the 1st quarter. Oakbrook Investments LLC now owns 36,600 shares of the biotechnology company’s stock worth $871,000 after purchasing an additional 500 shares in the last quarter. Cornerstone Advisors Inc. boosted its position in Exelixis by 26.5% in the 1st quarter. Cornerstone Advisors Inc. now owns 2,413 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 505 shares in the last quarter. MetLife Investment Advisors LLC boosted its position in Exelixis by 0.4% in the 1st quarter. MetLife Investment Advisors LLC now owns 182,944 shares of the biotechnology company’s stock worth $4,354,000 after purchasing an additional 642 shares in the last quarter. Highland Capital Management LLC boosted its position in Exelixis by 0.9% in the 1st quarter. Highland Capital Management LLC now owns 73,960 shares of the biotechnology company’s stock worth $1,760,000 after purchasing an additional 681 shares in the last quarter. Finally, Arizona State Retirement System boosted its position in Exelixis by 0.4% in the 1st quarter. Arizona State Retirement System now owns 215,511 shares of the biotechnology company’s stock worth $5,129,000 after purchasing an additional 919 shares in the last quarter. Institutional investors own 78.21% of the company’s stock.

Several equities analysts have recently issued reports on the stock. BidaskClub downgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday. Cowen upgraded shares of Twitter from an “underperform” rating to a “market perform” rating in a report on Tuesday, April 23rd. Zacks Investment Research downgraded shares of Great Portland Estates from a “hold” rating to a “sell” rating in a report on Tuesday, April 16th. Oppenheimer set a $13.00 price objective on shares of Alpine Immune Sciences and gave the company a “buy” rating in a report on Tuesday, March 19th. Finally, Morgan Stanley upped their price objective on shares of Zynga and gave the company an “overweight” rating in a report on Thursday, May 2nd. Two analysts have rated the stock with a sell rating, four have issued a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. Exelixis has an average rating of “Hold” and an average price target of $28.88.

About Exelixis

Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

See Also: Resistance Level

Insider Buying and Selling by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply